Table 1 Characteristics, methodological quality, treatment employed and outcome of the trials
Trial | Reference | Recruitment period | Publication year | Trial size | Origin of study | Randomization method | Stratification criteria | Trial type | Stage | Fraction with squamous cell (%) | Details of neoadjuvant treatment | HRa(95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dautzenberg et al. | 10 | 1985 to 1987 | 1990 | 26 | European | No details given | Not reported | Full text | Stage 1 to 3 | 81 | VCP × 2 | 1.10 (0.41 to 2.93) |
Roth et al. | 13,14 | 1987 to 1993 | 1998 | 60 | US | No details given | Not reported | Full text | Stage 3 only | 37 | CEP × 3 | 0.56 (0.31 to 1.01) |
Rosell et al. | 11, 12 | 1989 to 1991 | 1999 | 60 | European | Details given | Not reported | Full text | Stage 3 only | 70 | MIP × 3 | 0.50 (0.30 to 0.85) |
Zhou et al. | 21 | 1990 to 2001 | 2001 | 624 | Asian | Details given | Not reported | Full text | Stage 3 only | 51 | BAI/MVP/CAP/EP/VIP/GP/NP/PC/TN × 2 | 0.87 (0.71 to 1.07) |
De Pierre et al. | 15 | 1991 to 1997 | 2002 | 355 | European | No details given | Reported | Full text | Stage 1 to 3 | 74 | MIP × 2 | 0.83 (0.64 to 1.07) |
JCOG | 16 | 1993 to 1998 | 2003 | 62 | Asian | No details given | Reported | Full text | Stage 3 only | 24 | VP × 3 | 1.19 (0.69 to 2.05) |
Li et al. | 24 | 1990 to 1995 | 2003 | 137 | Asian | No details given | Not reported | Full text | Stage 3 only | 80 | CAP/EP × 1 | 0.68 (0.46 to 1.00) |
Liao et al. | 22 | 1995 to 1997 | 2003 | 211 | Asian | Details given | Reported | Full text | Stage 1 to 3 | - | MVP/MAP × 2 | 1.06 (0.76 to 1.48) |
Yao et al. | 23 | 1990 to 2002 | 2004 | 456 | Asian | Details given | Not reported | Full text | Stage 3 only | 55 | GP/NP/MVP/EP × 2 | 0.83 (0.67 to 1.03) |
Sorensen et al. | 17 | 1998 to 2004 | 2005 | 90 | US | No details given | Not reported | Abstract | Stage 1 to 3 | - | TP × 3 | 0.91 (0.55 to 1.50) |
s9900 | 18,19 | 1999 to 2004 | 2006 | 336 | European | No details given | Not reported | Full text | Stage 1 to 3 | 38 | PC × 3 | 0.79 (0.60 to 1.06) |
MRCLU22 | 6 | 1997 to 2005 | 2007 | 519 | European | No details given | Not reported | Full text | Stage 1 to 3 | 49 | MVP/MIP/NP/PC/DC/GP × 3 | 1.02 (0.80 to 1.31) |
Ch.E.S.T | 20, 25 | 2000 to 2004 | 2008 | 270 | European | No details given | Not reported | Abstract | Stage 1 to 3 | 41 | GP × 3 | 0.63 (0.46 to 0.87) |
Felip et al. | 26 | 2000 to 2007 | 2010 | 409b | European | No details given | Not reported | Full text | Stage 1 to 3 | 52 | PC × 3 | 0.96 (0.84 to 1.10) |